Contact this trialFirst, we need to learn more about you.
PD-1 Inhibitor
TAA-T Cells + Nivolumab for Lymphoma
Recruiting2 awardsPhase 1
Salt Lake City, Utah
This trial will enroll patients who have already tried other treatments and failed (group A) or who are at high risk of their lymphoma coming back after an autologous hematopoeitic stem cell transplant (group B).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service